Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses

Urology

Volumn 61, Issue 1, 2003, Pages 109-118

  Lotan, Yair ^a   Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOAVAILABILITY; BLADDER TUMOR; CANCER STAGING; CLINICAL TRIAL; CYSTOSCOPY; CYTOLOGY; EXTRACTION; FOLLOW UP; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; SCREENING; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY;

BAYES THEOREM; BIOPSY; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CONFIDENCE INTERVALS; HUMANS; META-ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0037253620     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02136-2     Document Type: Article

References (29)

1. Jaemal A., Thomas A., Murray T., et al. Cancer statistics 2002. CA Cancer J Clin. 52:2002;23-47.
2. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 164:2000;680-684.
3. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer progression and recurrence. J Urol. 130:1983;1083-1086.
4. Rubben H., Lutzeyer W., Fischer N., et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 139:1988;283-285.
5. Herr H.W. Intravesical BCG current results, natural history and implications for urothelial cancer prevention. J Cell Biochem Suppl. 161:1992;112-119.
6. Messing ECW: Urothelial tumors of the urinary tract, in Walsh PC, Retik AB, Vaughan ED Jr, et al (Eds): Campbells' Urology, 7th ed. Philadelphia, WB Saunders, 1998, Vol 3, pp 2327-2410.
7. Del Nero A., Esposito N., Curro A., et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer comparison with urinary cytology and BTA test. Eur Urol. 35:1999;93-97.
8. Giannopoulos A., Manousakas T., Mitropoulos D., et al. Comparative evaluation of the BTA stat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology. 55:2000;871-875.
9. Leyh H., Marberger M., Conort P., et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol. 35:1999;52-56.
10. Leyh H., Hall R., Mazeman E., et al. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology. 50:1997;49-53.
11. Raitanen M.P., Marttila T., Kaasinen E., et al. Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol. 163:2000;1689-1692.
12. Pode D., Shapiro A., Wald M., et al. Noninvasive detection of bladder cancer with the BTA stat test. J Urol. 161:1999;443-446.
13. Ramakumar S., Bhuiyan J., Besse J.A., et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 161:1999;388-394.
14. Sarosdy M.F., Hudson M.A., Ellis W.J., et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 50:1997;349-353.
15. Eddy DM, Hasselblad V, Shachter R: A Bayesian method for synthesizing evidence: the confidence profile method. Int J Technol Assess Health Care 6: 31-57, 1990.
16. Linn J.F., Lango M., Halachmi S., et al. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer. 74:1997;625-629.
17. Steiner G., Schoenberg M.P., Linn J.F., et al. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med. 3:1997;621-624.
18. Mao L., Schoenberg M.P., Scicchitano M., et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science. 271:1996;659-662.
19. Mourah S., Cussenot O., Vimont V., et al. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer. 79:1998;629-633.
20. Holmäng S., Hedelin H., Anderstrom C., et al. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 153:1995;1823-1827.
21. Herr H.W. Natural history of superficial bladder tumors 10- to 20-year follow-up of treated patients. World J Urol. 15:1997;84-88.
22. Sanchez-Carbayo M., Urrutia M., Silva J.M., et al. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer. Urology. 55:2000;526-532.
23. Sanchez-Carbayo M., Herrero E., Megias J., et al. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder. Urology. 54:1999;656-661.
24. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 162:1999;53-57.
25. Ellis W.J., Blumenstein B.A., Ishak L.M., et al. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology. 50:1997;882-887.
26. Klein A., Zemer R., Buchumensky V., et al. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer. 82:1998;349-354.
27. Vriesema J.L., Povcki M.H., Kiemeney L.N., et al. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: utility analysis. Urology. 56:2000;793-797.
28. Konety B.R., Nguyen T.S., Brenes G., et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol. 164:2000;634-639.
29. Lotan Y., Roehrborn C.G. Cost effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder a decision analytical approach. J Urol. 167:2002;75-79.